Market research
HEM.V Hemostemix Inc
V CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 16M
- P/E ratio
- Not available
- Analyst target
- 0.96
- Dividend yield
- Not available
- Beta
- 0.61
Profile
Company facts
- Exchange
- V
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA4236943060
- Market cap
- 16M
- P/E ratio
- Not available
- Analyst target
- 0.96
- Dividend yield
- Not available
- Beta
- 0.61
About
About Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HEM.V discussion.
5 years, 5 months ago
Hemostemix Inc is currently in a long term downtrend where the price is trading 16.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Hemostemix Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 18.5% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 60.1% to $-514K since the same quarter in the previous year.
Based on the above factors, Hemostemix Inc gets an overall score of 2/5.